openPR Logo
Press release

S1P receptor modulator Drugs Market To Witness a Major Overhaul between 2020 and 2030

10-21-2020 09:58 AM CET | Health & Medicine

Press release from: Persistence Market Research

S1P receptor performs basic biological processes such as cell proliferation, migration, cytoskeleton organization, immune cell trafficking and others. S1P receptor modulators are a type of immunomodulatory used in case of multiple sclerosis, psoriasis, inflammatory diseases, and cancer. S1P receptor modulators are used to control the release of lymphocytes in peripheral blood and reach the central nervous system. According to the Multiple Sclerosis Association of America, approximately 3.5 out of 1,000 people suffer from multiple sclerosis in the U.S. The global S1P receptor modulator drugs market is likely to grow with the increasing prevalence of multiple sclerosis.
The outbreak of novel coroanavirus has caused a disturbance in almost all industries, also impacted the global S1P receptor modulator drugs market. The pandemic has brought on many aspects, like falling business assurance, uncertainty about future, massive slowing of the supply chain, and others. S1P receptor modulator drugs market manufacturing industries are being shuttered around the world causing an unusual technology and business model transformation. There has been a disruption in the production and supply of S1P receptor modulator drugs due to the global restrictions. Also, due to the initial lockdown, the industries are now facing a demand shock with an uncertain recovery timeline.

To remain ‘ahead’ of your competitors, request for a sample here@ https://www.persistencemarketresearch.com/samples/31993

S1P receptor modulator Drugs Market: Drivers and Restraints-
The increasing prevalence of multiple sclerosis and psoriasis across the globe is the major factor driving the growth of the global S1P receptor modulator drugs market. The increasing advancement in technology and diagnosis and the treatment-seeking rate is also likely to drive the global S1P receptor modulator drugs market. Further, the rising R & D investments in developing countries are boosting the S1P receptor modulator drugs market growth. However, stringent regulations imposed by the regulatory authorities can restrain the growth of the global S1P receptor modulator drugs market.

Request For Table of Content (TOC) @ https://www.persistencemarketresearch.com/toc/31993

S1P receptor modulator Drugs Market: Segmentation
Based on the drug type, the global S1P receptor modulator drugs market can be segmented as:
• Fingolimod
• Ozanimod
• Siponimod
• Others
Based on the application, the global S1P receptor modulator drugs market is segmented as:
• Multiple sclerosis
• Psoriasis
• Cancer
• Others
Based on the distribution channel, the global S1P receptor modulator drugs market can be segmented as:
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
• Others
S1P receptor modulator Drugs Market: Overview
Based on the drug type, the fingolimod segment is expected to hold a major share in the S1P receptor modulator drugs market. Based on the application, the multiple sclerosis segment is expected to dominate the global S1P receptor modulator drugs market due to the increasing prevalence of the disease. Based on the distribution channel, retail pharmacies segment is expected to be the most dominating segment in the global S1P receptor modulator drugs market due to the increasing number of retail channels for prescription drugs. The online pharmacies segment is increased due to the rapid adoption of e-pharmacy and easy availability of drugs during the COVID-19.
S1P receptor modulator Drugs Market: Region-wise Outlook
North America is expected to dominate the global S1P receptor modulator drugs market, due to the rising prevalence of multiple sclerosis, increasing R & D investment, new product launches, and rising demand for immunomodulators in the region. North America is expected to be followed by Europe, due to the active government recommendations and favourable health reimbursement policies in the region. Asia-Pacific is expected to show rapid growth in the global S1P receptor modulator drugs market over the forecast period due to the improved distribution networks of pharmaceutical companies and rising healthcare expenditure in developing countries.
S1P receptor modulator Drugs Market: Key Market Participants
Some of the market participants in the global S1P receptor modulator drugs market identified across the value chain include: Novartis International AG, Bristol Myers Squibb, Pfizer Inc., Sanofi S.A, Merck & Co., Inc., Biogen Inc., Roche Holding AG, and others.
The report covers exhaust analysis on:
• S1P receptor modulator Drugs Market Segments
• S1P receptor modulator Drugs Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain
Regional analysis includes:
• North America (U.S., Canada)
• Latin America (Mexico. Brazil)
• Western Europe (Germany, Italy, France, U.K, Spain)
• Eastern Europe (Poland, Russia)
• Asia Pacific (India, ASEAN, Australia & New Zealand)
• China
• Japan
• Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

You can access Full report here @ https://www.persistencemarketresearch.com/checkout/31993

Contact Us:
305 Broadway
7th Floor
New York City, NY 10007
United States
USA - Canada Toll-Free: 800-961-0353
Email: sales@persistencemarketresearch.com

Persistence Market Research (PMR) is an innovative and specialized publisher of market intelligence reports and consulting services. Prompt delivery, in-depth research, and high quality are the sacrosanct principles of PMR.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release S1P receptor modulator Drugs Market To Witness a Major Overhaul between 2020 and 2030 here

News-ID: 2166441 • Views: 312

More Releases from Persistence Market Research

Technology Advancing at a Rapid Pace to Drive the Cell Banking Outsourcing Marke …
A cell bank refers to a facility that store cells derived from various body fluids and organ tissue for future needs. The bank store the cells with detailed characterization of the cell line hence decrease the chances of cross contamination. Cell banking outsourcing industry involves collection, storage, characterization, and testing of cells, cell lines, and tissues. Cell banks provide cells, cell lines, and tissues for R&D, production of biopharmaceuticals with
The Electron Microscopy Sample Preparation Market to Continue to be Incremental …
Electron microscopes use accelerated beams of electrons as source of illumination. Resolving power of electron microscope is much higher than light microscope and thus electron microscope can magnify even the smallest structure of the sample. Electron microscope has the efficiency to produce resolution up to 50 Pico meter and magnification up to 10,000,000x. These high specifications make every detail of the sample clearly visible. Sample preparation is the initial operation
The Flavoured Veterinary Medications Market to record a remarkable growth in the …
Flavored Veterinary Medications are the medicines available in different flavors for the diagnosis, treatment and prevention of diseases in animals or birds. Veterinarians give the right advice to pet owners to take proper care of their pets and the right medication too. Sometimes a problem arises that pets are do not intake proper medication because of the taste. For example cats don’t like pills but like tuna, dogs don’t like
Incremental Sales to Drive the Sleep Disorder Therapeutics Market from 2020 to 2 …
Sleep disorders include a variety of complications related to sleep and have a high prevalence across the globe. Based on these complications, sleep disorders can be classified into three categories- lack of sleep which includes insomnia, excessive sleep which includes narcolepsy and disturbed sleep which include sleep apnea and Rapid eye movement (REM) disorder. Insomnia may arise as result of unhealthy diet, emotional dreams, stress, and many other factors. Insomnia

All 5 Releases


More Releases for S1P

Multiple Sclerosis Market Is Expected to Exhibit an Upward Growth Trend Across G …
ResearchMoz include new market research report "Multiple Sclerosis: Dynamic Market Forecast to 2026" to its huge collection of research reports. Multiple Sclerosis (MS) is a rapidly evolving field in which new developments are constantly influencing the market landscape. The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the MS space, including regulatory, commercial, and clinical events as well as understand how all of these events
Multiple Sclerosis Market Forecast to 2026: Novartis, AB Science, Celgene, Actel …
Researchmoz added Most up-to-date research on "Multiple Sclerosis: Dynamic Market Forecast to 2026" to its huge collection of research reports. Multiple Sclerosis: Dynamic Market Forecast to 2026 Summary Multiple Sclerosis (MS) is a rapidly evolving field in which new developments are constantly influencing the market landscape. The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the MS space, including regulatory, commercial, and clinical events as well
Engaged in Sphingolipid Research? Check Out Echelon's New S1P antibody Z-P300!
Sphingosine 1-Phosphate (S1P) is a key component of the sphingolipid signaling cascade. Recently, scientific literature has suggested that S1P is a potent tumorigenic growth factor that is likely released from tumor cells and that S1P may be a novel biomarker for early stage cancer detection. Sphingosine kinase has also been shown to be up-regulated in a variety of cancer types. S1P antibody (LT1002) was originally developed and patented at Lpath Therapeutics. Echelon
Multiple Sclerosis Global Key Players - Biogen, Merck KGaA, Teva, Sanofi, and No …
Multiple Sclerosis Overview Multiple Sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection, and neurodegeneration within the central nervous system. It is the most common cause of non-traumatic neurological disability in young adults, afflicting at least 2.5 million people worldwide. In most patients, the disease is characterized initially by episodes of reversible neurological deficits, which is often followed by progressive neurological deterioration over time. The precise etiology of
ISM at the A+A 2015 – The most safe of encounters
The trade fair appearance of ISM 2015 at the A+A with its two PPE-brands ALBATROS and PU-MA SAFETY is dedicated to new concepts, strong design and innovative products. Based on reliability and quality, ISM would like to expand its market leadership in safety- and work shoes with ALBATROS and PUMA SAFETY. ALBATROS as well as PUMA SAFETY will present a broad product range at the A+A. There are hardly any
Proteros announces the appointment of Dr. Klaus Hinterding as Chief Scientific O …
Martinsried, Germany, February 9, 2012. Proteros biostructures GmbH (Proteros) announced today that Dr. Klaus Hinterding, formerly at Hoffmann-La Roche Ltd. (Roche), has joined the company as Chief Scientific Officer and member of the management board. Dr. Hinterding brings to Proteros considerable pharmaceutical industry experience that spans early research through to clinical development in various therapeutic areas. At Novartis, his research contributed to the understanding of the mode-of-action of GilenyaTM, licensed for